Renal Cancer VL

The Role of Cytoreductive Nephrectomy in Patients with Metastatic Renal Cell Carcinoma - Neeraj Agarwal, MD

Details
Neeraj Agarwal, MD discusses the recent update to the CARMENA trial which was presented at ASCO 2019. The Phase 3 non-inferiority CARMENA trial comparing sunitinib versus nephrectomy followed by sunitinib established that patients could avoid nephrectomy without compromising survival. This benefit was seen in both the intermediate and poor risk subgroups. In the updated data presented at ASCO 2019...

Advances of Systemic Treatments in Renal Cell Carcinoma - Jens Bedke

Details
Jens Bedke enthusiastically discusses the transformation in first-line treatment of RCC from monotherapy, which has been the standard of care on the treatment of RCC to now combination therapies. The first-line therapy with a combination of an immune checkpoint inhibitor and a tyrosine kinase inhibitor (TKI) improved outcomes in patients with clear-cell metastatic renal cell carcinoma (mRCC), as c...

Patient Advocacy and Resources in Kidney Cancer - Dena Battle

Details
Dena Battle, President KCCure joins Jaime Landman and Monty Pal for a discussion on development and establishing resources to assist in the fight against kidney cancer. KCCure, is a research organization that funds high-impact, high-risk kidney cancer research through a peer-review processthrough an expert team of kidney cancer specialists, patients, caregivers, and kidney cancer advocates. The gr...

Treatment Strategies in Kidney Cancer and the Results of CARMENA - Toni Choueiri

Details
(Length of Discussion: 9 min) Alicia Morgans and Toni Choueiri provide a review of the historical background evolving from the era of targeted therapy to the current landscape in kidney cancer incorporating the surprising results from the CARMENA trial. Biographies: Toni K. Choueiri, MD, Jerome and Nancy Kohlberg Professor of Medicine, Harvard Medical School, Attending Physician, Solid Tumor Oncol...

Over-treatment of Renal Tumors: The Turtle in the Room - Robert G. Uzzo

Details
(Length of discussion - 11 minutes) Kidney cancer, like all cancers, has a spectrum of risk. There are groups of patients with incidentally detected asymptomatic, small renal masses that act relatively indolent and are often over-diagnosed and over-treated in some patients. The issue is defining who they are when they should or should not be treated. Related Content: Watch: Adjuvant Therapies for...

Adjuvant Therapies for Renal Cell Carcinoma - Robert Uzzo

Details
(Length of discussion - 21 minutes) David Crawford discusses adjuvant therapy in kidney cancer with Robert Uzzo, and the fact that although there have been three decades of trials, there is still no approved therapies to treat the disease. However, Dr. Uzzo points to the S-TRAC trial as a step forward in that research space. Related Content: Watch: Over-treatment of Renal Tumors: The Turtle in the...
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe